Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An Ebola vaccine has been shown to provide immunity for up to a year after immunisation in all of those immunised in a new study.

Ebola vaccine offers long lasting immunity

Image courtesy of Shutterstock

The findings, based on a Phase 1 clinical trial involving 75 healthy subjects, were published in the Journal of the American Medical Association (JAMA).

The study was led by the Oxford Vaccine Group at the University of Oxford. It tested the prime-boost Ebola vaccine regimen being developed by Janssen Vaccines & Prevention B.V. that is based on Janssen’s AdVac technology and MVA-BN technology from Bavarian Nordic A/S. Healthy volunteers were given one vaccine dose to prime their immune system, and the alternative vaccine to boost their immune response. Additional Phase 1, 2 and 3 studies are ongoing to build on these findings.

Read more